Moreover, the selective-PI3K inhibitor ZSTK474, in an optimal dose, deletes Treg cells specifically, and, intriguingly, PI3K inhibition promoted the differentiation into tumor-specific CD8+ memory T cells, which contributed to a more robust immune response [42]. Here, CD8A is linked to neoplasm.